Health & Fitness:Medicine
We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?
Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP
Guest Panelist: Dawn Fuke, PharmD, BCPS
Music by Good Talk
Breaking the SABA-only Rescue Habit: Two Drugs Are Better Than One
Are You Sure? Tolerance of Uncertainty and the Risk of Stress-Related Harm
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Educating Patients and Prescribers About Deprescribing to Reduce Medication Burden May Not Be Enough
Treating mild hypertension during pregnancy: Time for a new CHAPter!
Finally! Something FDA-Approvable for Non-alcoholic Steatohepatitis (NASH)?
Managing Pain in Patients with High Blood Pressure: Is There No Safe PATH?
Continuous Glucose Monitors (CGMs) - Patient Management Strategies and Getting Paid!
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Annual Wellness Visits: Pharmacists Closing Care Gaps
FOMO — Keeping Up With the Primary Literature
Could a DOAC Replace Warfarin to Treat the Thrombotic Antiphospholipid Syndrome?
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Don’t Miss a Beat: The Importance of Influenza Vaccination in Patients with Coronary Disease
Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Top Ten Things Every Clinician Should Know about the 2022 Medical Standard of Care for Diabetes
On the Look Out for Prescribing Cascades
Thiazides in Chronic Kidney Disease: New Evidence Challenging Old Dogma
Sequential Additions or Multicomponent Combination? Should Our Approach to Hypertension Be Re-examined?
Copyright © 2006-2022 Podbean.com